genetically
Figure 2: hMSCs can be genetically modified with adenoviral vector to secrete high levels of biologically active ECSOD. (A) Photomicrograph showing colony-forming unit (CFU) of hMSCs in 14-day culture of 1×105 human bone marrow mononuclear cells (BM-MNCs). The 14-day culture of 1×105 human peripheral blood mononuclear cells (PB-MNCs) was used as a negative control. (B) Quantification of CFU of hMSCs in 14-day culture of 1×105 human BM-MNCs or PB-MNCs. (C) Flow cytometric analysis showing typical phenotype of hMSCs. (D) Spectral karyotyping (SKY) cytogenetic analysis showing hMSCs with a normal diploid pattern of male human origin (46, XY). (E) Photomicrographs showing dose-dependent expression of nuclear-targeted β-galactosidase by ntlacZ-hMSCs. Original magnification: 100X. (F) Dose-dependent, high-level secretion of biologically active ECSOD by ECSOD-hMSCs. Data were expressed as mean ± SEM (n = 3) and analyzed statistically using a one-way analysis of variance (ANOVA) followed by post-hoc analysis with Tukey test. *P < .001 versus MOI 0; **P < .001 versus MOI 0 or 300.